Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cipla
US Department of Justice
McKesson
Baxter
Fish and Richardson
Express Scripts
Merck
Farmers Insurance

Generated: December 19, 2018

DrugPatentWatch Database Preview

JUXTAPID Drug Profile

« Back to Dashboard

Which patents cover Juxtapid, and what generic alternatives are available?

Juxtapid is a drug marketed by Aegerion and is included in one NDA. There are nine patents protecting this drug.

This drug has ninety-two patent family members in thirty-seven countries.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lomitapide mesylate profile page.

Drug patent expirations by year for JUXTAPID
Generic Entry Opportunity Date for JUXTAPID
Generic Entry Date for JUXTAPID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for JUXTAPID
1-(4-{9-[(2,2,2-trifluoroethyl)carbamoyl]-9H-fluoren-9-yl}butyl)-4-({[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)piperidinium methanesulfonate
202914-84-9
2522AH
9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-(4-(4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1-piperidinyl)butyl)-, methanesulfonate
AEGR-733 mesylate;BMS-201038 mesylate;AEGR733 mesylate;BMS201038 mesylate;AEGR 733 mesylate;BMS 201038 mesylate
AKOS025149431
BMS 201038-04
BMS-201038-04
C39H37F6N3O2.CH4O3S
CHEBI:72299
CHEMBL2105662
CS-3424
D09638
DTXSID60174170
EX-A502
FT-0700260
HY-14668
J-690260
Juxtapid (TN)
KB-75599
Lojuxta (TN)
Lomitapide (mesylate)
Lomitapide mesilate (JAN)
Lomitapide mesylate
Lomitapide mesylate (USAN)
Lomitapide mesylate [USAN]
lomitapide methanesulfonate
lomitapide monomesylate
MFCD19443682
MolPort-035-789-730
N-(2,2,2-trifluoroethyl)-9-[4-(4-{2-[4-(trifluoromethyl)phenyl]benzamido}piperidin-1-yl)butyl]-9H-fluorene-9-carboxamide; methanesulfonic acid
N-(2,2,2-trifluoroethyl)-9-{4-(4-({(4'-(trifluoromethyl)biphenyl-2-yl)carbonyl}amino)piperidin-1-yl)butyl}-9H-fluorene-9-carboxamide methanesulfonate
N-(2,2,2-trifluoroethyl)-9-{4-[4-({[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)piperidin-1-yl]butyl}-9H-fluorene-9-carboxamide methanesulfonate
QC-11679
QKVKOFVWUHNEBX-UHFFFAOYSA-N
s7633
SCHEMBL2731380
UNII-X4S83CP54E
X4S83CP54E

US Patents and Regulatory Information for JUXTAPID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-005 Apr 23, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-004 Apr 23, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-005 Apr 23, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-006 Apr 23, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for JUXTAPID

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-001 Dec 21, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-002 Dec 21, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-003 Dec 21, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for JUXTAPID

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0140001 00107 Estonia ➤ Try a Free Trial PRODUCT NAME: LOMITAPIID;REG NO/DATE: K(2013)5153(LOPLIK) 05.08.2013
8 Finland ➤ Try a Free Trial
2014 00002 Denmark ➤ Try a Free Trial PRODUCT NAME: LOMITAPID OG ENHVER TERAPEUTISK AEKVIVALENT FORM DERAF, SOM BESKYTTET I GRUNDPATENTET; REG. NO/DATE: EU/1/13/851/001-003 20130731
2014000003 Germany ➤ Try a Free Trial PRODUCT NAME: LOMITAPID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON ODER DAS PIPERIDIN-N-OXID DAVON; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130731
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cipla
US Department of Justice
McKesson
Baxter
Fish and Richardson
Express Scripts
Merck
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.